• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Thursday, October 31, 2019

    Offline Date

    Thursday, April 30, 2020

    ACPE Expiration Date

    Monday, October 31, 2022

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      Venous thromboembolism (VTE) is common in cancer patients, resulting in considerable morbidity and mortality. These patients have higher rates of both VTE recurrence and bleeding compared with the non-cancer VTE patient population. Low molecular weight heparins (LMWH) have been the standard of care to treat cancer-associated thrombosis for decades, but several studies have been published and more still are underway describing the use of direct oral anticoagulants in these patients. These drugs are an attractive option as they do not require injection nor do they require routine laboratory monitoring. Additionally, recent data has emerged describing the use of DOACs for primary prevention of cancer-associated VTE. This presentation will discuss these topics, review the published studies of DOACs for treatment and prevention of cancer-associated VTE, and offer an evidence-based approach to the selection of an anticoagulant agent in cancer patients based on disease- and patient-related characteristics.

      Handouts

      • Slide Document :   ce_4_slides.pdf

      Financial Support By

      joint funding from Advanced Accelerator Applications, a Novartis Company, BMS and Pfizer Alliance, Celgene Corporation, Merck & Co., Inc, and Pfizer
    • Pharmacist

      Describe the findings of recent studies comparing direct oral anticoagulants (DOACs) with low molecular weight heparins for the treatment of cancer-associated thrombosis.
      Describe the studies examining the utility of DOACs for primary prevention of venous thromboembolism in cancer patients.
      Recognize the unique aspects of the cancer patient population that make anticoagulation higher risk in these patients.
      Identify cancer patient subpopulations for whom DOACs are optimal and those subpopulations for whom DOACs should be avoided.

      Nurse

      Identify cancer patient subpopulations for whom DOACs are optimal and those subpopulations for whom DOACs should be avoided.
      Describe the studies examining the utility of DOACs for primary prevention of venous thromboembolism in cancer patients.
      Describe the findings of recent studies comparing direct oral anticoagulants (DOACs) with low molecular weight heparins for the treatment of cancer-associated thrombosis.
      Recognize the unique aspects of the cancer patient population that make anticoagulation higher risk in these patients.
    • Activity Type

      Application

      CE Broker

      20-747580

      Universal Activity Number

      Pharmacist 0798-0000-19-187-H01-P
      Nurse 0798-0000-19-187-H01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.

    • Faculty

      Hanny  Al-Samkari, MD, BA, BS
      Attending Physician, Clinical Assistant in Medicine Division of Hematology Oncology, Massachusetts General Hospital

    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).